ALLAKOS INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.425 USD | -1.72% |
|
+17.50% | -48.35% |
| May. 09 | Allakos Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 15 | North American Morning Briefing : Inflation Worries Continue to Weigh on Mood | DJ |
Presenter SpeechRobert Alexander (Executives)So my name's Robert Alexander, I'm the President ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Allakos Inc. is a clinical-stage biotechnology company, which is engaged in the development of therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases. The Companyâs most advanced product candidate, AK006, is in a Phase I clinical trial. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It is developing AK006 for the treatment of CSU and potentially other indications. AK006 has completed preclinical testing, and in these studies, it has demonstrated that binding of AK006 to Siglec-6 inhibits multiple modes of mast cell activation, including IgE, IL-33, KIT, C5a and MRGPR-X2. In addition to mast cell inhibition, AK006 reduced human tissue mast cells via ADCP in the presence of activated macrophages. The Company is also developing lirentelimab (AK002) and, in conjunction with the Phase II, lirentelimab results in atopic dermatitis and chronic spontaneous urticaria.
Calendar
2024-05-24
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
1.45
USD
Average target price
2.9
USD
Spread / Average Target
+100.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -48.35% | 128M | |
| +8.87% | 114B | |
| +11.60% | 104B | |
| -12.56% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -3.21% | 17.89B | |
| +7.77% | 14.28B | |
| +35.85% | 12.55B |
- Stock Market
- Equities
- ALLK Stock
- News Allakos Inc.
- Transcript : Allakos Inc. - Analyst/Investor Day
